Prof. Jur Ten Berg Presents Clinical Trial Results of Zalunfiban (RUC-4), a Novel Platelet Glycoprotein IIb/IIIa Inhibitor (GPI), in STEMI Patients

Data presented as Late Breaking Trial at EuroPCR and published in Eurointervention show a single subcutaneous injection of RUC-4 consistently induced high-grade inhibition of platelet function.

Watch the 6min interview with prof. Jur Ten Berg and prof. Arnoud Van ‘t Hof at EuroPCR2021 here.

“This clinical study in STEMI patients showed that zalunfiban (RUC-4) rapidly achieved dose-dependent high grade inhibition of platelet function, consistently reaching a level of inhibition of platelet function at the highest dose that has been shown to correlate with improved clinical outcomes in patients treated with other GPIs,” said Jur ten Berg, M.D., Ph.D., M.Sc., FESC, FACC, Director of the Cardiology Training Program, Head of the St. Antonius Center for Platelet Function Studies at the St Antonius Hospital and professor antithrombotic therapy in cardiac interventions, MUMC⁺, the Netherlands, and principal investigator of the CEL-02 clinical study.

Zalunfiban (RUC-4), a next generation GPI, is specifically designed to be administered subcutaneously to inhibit platelet aggregation for a first-point-of-medical contact treatment to improve outcomes for STEMI patients. Inhibiting platelet aggregation can slow or stop blood clot formation leading to coronary artery blockage, and in turn, can stop or prevent a heart attack.

Arnoud van ’t Hof, M.D., Ph.D., FESC, Head of the Department of Interventional Cardiology, MUMC⁺, the Netherlands, and principal investigator of the CELEBRATE study, said: “This study continues to build on the data supporting the potential of zalunfiban as a first point-of-contact STEMI therapy to fulfil a significant unmet medical need in the pre-hospital phase of heart attack care. We are continuing to enrol in the CELEBRATE, and we believe this study will provide important clinical data to support the use of zalunfiban in the pre-hospital treatment of STEMI patients.”

Watch the full presentation here.

Diagram is the Contract Research Organisation (CRO) of both the CEL-02 clinical study and CELEBRATE. 

Click here for the press release of the study sponsor CeleCor Therapeutics, Inc.

CeleCor Therapeutics, Inc. is a biotechnology company focused on developing a first-point-of-contact therapy to improve the treatment of serious heart attacks, specifically ST-segment Elevation Myocardial Infarction (STEMI). For more information, visit www.celecor.com.